4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Belimumab: a step forward in the treatment of systemic lupus erythematosus.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: Systemic Lupus Erythematosus (SLE) is a chronic B cell-mediated autoimmune disease which can potentially involve several organs and systems. The development of SLE is associated with a complexity of genetic, hormonal and environmental factors leading to immune deregulation and production of autoantibodies. Therefore, novel therapies have focused on B cells as key effectors of SLE pathogenesis. Belimumab is a fully humanized monoclonal antibody that antagonizes B-lymphocyte stimulator (BLyS); it is the first and the only biological drug approved for SLE in over 50 years.Areas covered: In this review we discuss the pharmacological properties of belimumab, new recommendations for its use in clinical practice and its evidence of efficacy and safety based on clinical trial and real-life data.Expert opinion: Efficacy and safety of belimumab in clinical practice have been well established. To date, it is known that early introduction of belimumab in SLE can maximize the efficacy of the drug. A number of questions are still open, such as the timing of belimumab discontinuation and its possible association with other biological drugs, which need to be assessed in future studies.

          Related collections

          Author and article information

          Journal
          Expert Opin Biol Ther
          Expert opinion on biological therapy
          Informa UK Limited
          1744-7682
          1471-2598
          May 2021
          : 21
          : 5
          Affiliations
          [1 ] Division of Rheumatology, University of Padova, Padova, Italy.
          Article
          10.1080/14712598.2021.1895744
          33630721
          eccd9eb1-73a8-4c58-a3c7-a9edcd6d51df
          History

          systemic lupus erythematosus,B lymphocyte inhibition,belimumab,drug efficacy

          Comments

          Comment on this article